{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-032011","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.663839+00:00","generated_at":"2026-05-19T02:53:51.488865+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Avalo Therapeutics appoints former ChemoCentryx CMO Rita Jain to board","bullets":["Dr. Rita Jain appointed to Avalo's Board of Directors effective June 17, 2025.","She previously served as EVP and CMO at ChemoCentryx, advancing Tavneos for ANCA vasculitis.","Received initial non-qualified stock option for 40,200 shares, vesting over three years.","Board also adopted Amended Non-Employee Director Compensation Plan to attract qualified directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-032011","json":"https://secwatch.observer/filing/0001628280-25-032011.json","markdown":"https://secwatch.observer/filing/0001628280-25-032011.md","text":"https://secwatch.observer/filing/0001628280-25-032011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025032011/0001628280-25-032011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025032011/avtx-20250617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T02:53:51.488865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7036c17f56","claim":"Rita Jain was appointed as Director at Avalo Therapeutics, Inc..","evidence_excerpt":"On June 17, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Rita Jain, M.D. to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025032011/0001628280-25-032011-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}